Proposed direct test of a certain type of noncontextuality in quantum mechanics

The noncontextuality of quantum mechanics can be directly tested by measuring two entangled particles with more than two outcomes per particle. The two associated contexts are "interlinked" by common observables.Comment: 9 pages 2 figure

Non-Contextual Hidden Variables and Physical Measurements

For a hidden variable theory to be indistinguishable from quantum theory for finite precision measurements, it is enough that its predictions agree for some measurement within the range of precision. Meyer has recently pointed out that the Kochen-Specker theorem, which demonstrates the impossibility of a deterministic hidden variable description of ideal spin measurements on a spin 1 particle, can thus be effectively nullified if only finite precision measurements are considered. We generalise this result: it is possible to ascribe consistent outcomes to a dense subset of the set of projection valued measurements, or to a dense subset of the set of positive operator valued measurements, on any finite dimensional system. Hence no Kochen-Specker like contradiction can rule out hidden variable theories indistinguishable from quantum theory by finite precision measurements in either class.Comment: Typo corrected. Final version: to appear in Phys. Rev. Let

A feasible "Kochen-Specker" experiment with single particles

We present a simple experimental scheme which can be used to demonstrate an all-or-nothing type contradiction between non-contextual hidden variables and quantum mechanics. The scheme, which is inspired by recent ideas by Cabello and Garcia-Alcaine, shows that even for a single particle, path and spin information cannot be predetermined in a non-contextual way.Comment: 4 pages, 3 figure

Experimentally testable state-independent quantum contextuality

We show that there are Bell-type inequalities for noncontextual theories that are violated by any quantum state. One of these inequalities between the correlations of compatible measurements is particularly suitable for testing this state-independent violation in an experiment.Comment: REVTeX4, 4 pages, 1 figur

Kochen-Specker theorem for a single qubit using positive operator-valued measures

A proof of the Kochen-Specker theorem for a single two-level system is presented. It employs five eight-element positive operator-valued measures and a simple algebraic reasoning based on the geometry of the dodecahedron.Comment: REVTeX4, 4 pages, 2 figure

Finite precision measurement nullifies the Kochen-Specker theorem

Only finite precision measurements are experimentally reasonable, and they cannot distinguish a dense subset from its closure. We show that the rational vectors, which are dense in S^2, can be colored so that the contradiction with hidden variable theories provided by Kochen-Specker constructions does not obtain. Thus, in contrast to violation of the Bell inequalities, no quantum-over-classical advantage for information processing can be derived from the Kochen-Specker theorem alone.Comment: 7 pages, plain TeX; minor corrections, interpretation clarified, references update

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma

Classical Hodgkin's lymphoma (cHL), although originating from B-cells, is characterized by the virtual lack of gene products whose expression constitutes the B-cell phenotype. Epigenetic repression of B-cell-specific genes via promoter hypermethylation and histone deacetylation as well as compromised expression of B-cell-committed transcription factors were previously reported to contribute to the lost B-cell phenotype in cHL. Restoring the B-cell phenotype may not only correct a central malignant property, but render cHL susceptible to clinically established antibody therapies targeting B-cell surface receptors or small compounds interfering with B-cell receptor signaling. We conducted now a high-throughput pharmacological screening based on more than 28,000 compounds in cHL cell lines carrying a CD19 reporter to identify drugs that promote re-expression of the B-cell phenotype. Three chemicals were retrieved that robustly enhanced CD19 transcription. Subsequent chromatin immunoprecipitation-based analyses indicated that action of two of these compounds was associated with lowered levels of the transcriptionally repressive lysine 9-trimethylated histone H3 mark at the CD19 promoter. Moreover, the anti-leukemia agents all-trans retinoic acid and arsenic trioxide (ATO) were found to reconstitute the silenced B-cell transcriptional program and reduce viability of cHL cell lines. When applied in combination with a screening-identified chemical, ATO evoked re-expression of the CD20 antigen, which could be further therapeutically exploited by enabling CD20 antibody-mediated apoptosis of cHL cells. Furthermore, restoration of the B-cell phenotype also rendered cHL cells susceptible to the B-cell Non-Hodgkin's lymphoma-tailored small compound inhibitors Ibrutinib and Idelalisib. In essence, we report here a conceptually novel, re-differentiation-based treatment strategy for cHL

Causality - Complexity - Consistency: Can Space-Time Be Based on Logic and Computation?

The difficulty of explaining non-local correlations in a fixed causal structure sheds new light on the old debate on whether space and time are to be seen as fundamental. Refraining from assuming space-time as given a priori has a number of consequences. First, the usual definitions of randomness depend on a causal structure and turn meaningless. So motivated, we propose an intrinsic, physically motivated measure for the randomness of a string of bits: its length minus its normalized work value, a quantity we closely relate to its Kolmogorov complexity (the length of the shortest program making a universal Turing machine output this string). We test this alternative concept of randomness for the example of non-local correlations, and we end up with a reasoning that leads to similar conclusions as in, but is conceptually more direct than, the probabilistic view since only the outcomes of measurements that can actually all be carried out together are put into relation to each other. In the same context-free spirit, we connect the logical reversibility of an evolution to the second law of thermodynamics and the arrow of time. Refining this, we end up with a speculation on the emergence of a space-time structure on bit strings in terms of data-compressibility relations. Finally, we show that logical consistency, by which we replace the abandoned causality, it strictly weaker a constraint than the latter in the multi-party case.Comment: 17 pages, 16 figures, small correction

NMR quality control of fragment libraries for screening

Fragment-based screening has evolved as a remarkable approach within the drug discovery process both in the industry and academia. Fragment screening has become a more structure-based approach to inhibitor development, but also towards development of pathway-specific clinical probes. However, it is often witnessed that the availability, immediate and long-term, of a high quality fragment-screening library is still beyond the reach of most academic laboratories. Within iNEXT (Infrastructure for NMR, EM and X-rays for Translational research), a EU-funded Horizon 2020 program, a collection of 782 fragments were assembled utilizing the concept of "poised fragments" with the aim to facilitate downstream synthesis of ligands with high affinity by fragment ligation. Herein, we describe the analytical procedure to assess the quality of this purchased and assembled fragment library by NMR spectroscopy. This quality assessment requires buffer solubility screening, comparison with LC/MS quality control and is supported by state-of-the-art software for high throughput data acquisition and on-the-fly data analysis. Results from the analysis of the library are presented as a prototype of fragment progression through the quality control process

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)

ObjectiveThe objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. MethodsThe GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud's and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, the investigators rated their patients as non-, partial or complete responders based on clinical grounds. ResultsData from 85 SLE patients were collected, 69 female and 16 male, with a mean disease duration of 9.8 years. The mean follow-up period was 9.67.4 months, resulting in 66.8 patient years of observation. A complete response was reported in 37 patients (46.8%), partial response in 27 (34.2%), no response in 15 (19.0%). On average, major clinical as well as laboratory efficacy parameters improved substantially, with the SLEDAI decreasing significantly from 12.2 to 3.3 points. Concerning safety, one infusion reaction leading to discontinuation of treatment occurred. Infections were reported with a rate of 19.5 (including six severe infections) per 100 patient years. ConclusionWith the restrictions of a retrospective data collection, the results of this study confirm data of other registries, which suggest a favourable benefit-risk ratio of rituximab in patients with treatment-refractory SLE